

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Henlius Biotech, Inc.

上海復宏漢霖生物技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2696)

VOLUNTARY ANNOUNCEMENT

INCLUSION OF THE COMPANY AS A CONSTITUENT STOCK OF HANG SENG COMPOSITE INDEX

This announcement is made by Shanghai Henlius Biotech, Inc. (the “**Company**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest development of the Company.

The board of directors of the Company (the “**Board**”) is pleased to announce that, according to the results of the quarterly review of the Hang Seng Family of Indexes for the period ended 30 June 2026 announced by Hang Seng Indexes Company Limited on 21 August 2026, the Company has been selected and will be included as a constituent stock of the Hang Seng Composite Index, with effect from 7 September 2026.

The Hang Seng Composite Index offers a comprehensive Hong Kong market benchmark that covers about the top 95th percentile of the total market capitalisation of companies listed on the Main Board of the Stock Exchange of Hong Kong. Following its inclusion as a constituent stock of the Hang Seng Composite Index, the Company's H shares are expected to meet the eligibility criteria for inclusion under the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect.

The Company's inclusion in the Hang Seng Composite Index reflects the capital market's recognition of the company's value and growth potential, which will help broaden the Company's shareholder base and increase the trading liquidity of its shares.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

On behalf of the Board
Shanghai Henlius Biotech, Inc.
Wenjie Zhang
Chairman

Hong Kong, 21 August 2026

As at the date of this announcement, the board of directors of the Company comprises Mr. Wenjie Zhang as the chairman and non-executive director, Dr. Jun Zhu as the executive director, Mr. Qiyu Chen, Mr. Yuqing Chen, Ms. Xiaohui Guan, Dr. Yi Liu and Dr. Xingli Wang as the non-executive directors, and Mr. Tak Young So, Dr. Lik Yuen Chan, Dr. Ruilin Song and Mr. Yihao Zhang as the independent non-executive directors.